HR-positive metastatic breast cancer after CDK4/6 inhibitors: the decisions you may face
5 treatment settings, 5 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
ESR1-mutant disease after a CDK4/6 inhibitor
Elacestrant (EMERALD), imlunestrant (EMBER-3) or vepdegestrant; where available, a switch to camizestrant at the moment ESR1 appears in plasma while continuing the CDK4/6 inhibitor (SERENA-6).
Elacestrant was the first oral oestrogen-receptor degrader (2023), for ESR1-mutant breast cancer detected by blood test.
Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation.
Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.
Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations.
A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.
- Minimally invasive, repeatable
- Whole-body clonal picture
- Tests ElacestrantER+/HER2- advanced breast cancer after 1-2 endocrine lines including a CDK4/6 inhibitor: elacestrant vs standard endocrine therapy
PFS HR 0.55 in ESR1-mutant.
Progression-free survival (ESR1-mutant) (months): Elacestrant 3.8 (n=115) vs Standard endocrine therapy 1.9 (n=113) · HR 0.55 · source - Tests ImlunestrantER+/HER2- advanced breast cancer after ≥1 endocrine line: imlunestrant vs standard endocrine therapy, and imlunestrant + abemaciclib vs imlunestrant
PFS HR 0.62 (ESR1-mutant, monotherapy); HR 0.57 (combination vs monotherapy).
Progression-free survival, ESR1-mutant (imlunestrant vs standard ET) (months): Imlunestrant 5.5 vs Standard endocrine therapy 3.8 · HR 0.62 · source - First-line HR+/HER2- advanced breast cancer on AI + CDK4/6 with an ESR1 mutation detected in ctDNA before radiographic progression: switch to camizestrant + CDK4/6 vs continue AI + CDK4/6
PFS 16.0 vs 9.2 months, HR 0.44.
Progression-free survival (months): Switch to camizestrant + CDK4/6 16 (n=157) vs Continue AI + CDK4/6 9.2 (n=158) · HR 0.44 · source
- Take with food to reduce nausea.
- Low shedding in some tumours (brain, early-stage)
- Clonal haematopoiesis false positives
- Between Elacestrant, Imlunestrant, Camizestrant and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in EMERALD and EMBER-3, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (esr1-mutant disease after a cdk4/6 inhibitor), which of the standard options do you recommend and why?Why: Guideline options include: Elacestrant (EMERALD), imlunestrant (EMBER-3) or vepdegestrant; where available, a switch to camizestrant at the moment ESR1 appears in plasma while continuing the CDK4/6 inhibitor (SERENA-6).
- Am I a candidate for Elacestrant, Imlunestrant, Camizestrant or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EMERALD and EMBER-3 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
PIK3CA, AKT1 or PTEN alteration
Capivasertib with fulvestrant (CAPItello-291); alpelisib with fulvestrant for PIK3CA (SOLAR-1); inavolisib with palbociclib and fulvestrant for PIK3CA-mutant disease relapsing during or soon after adjuvant endocrine therapy (INAVO120).
Capivasertib (Truqap) is the first AKT inhibitor, for breast cancer with PI3K-pathway mutations and, since 2026, for prostate cancer with PTEN loss.
Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs are displacing it.
Inavolisib is a PI3K drug that also destroys the mutant protein, approved in 2024 with palbociclib and fulvestrant for PIK3CA-mutant breast cancer.
Fulvestrant is a monthly intramuscular injection that degrades the oestrogen receptor rather than blocking it, the endocrine backbone paired with CDK4/6, PI3K and AKT inhibitors once aromatase inhibitors fail. Slow uptake and incomplete receptor degradation drove the search for oral degraders.
- Tests CapivasertibHR+/HER2- advanced breast cancer after aromatase inhibitor (± CDK4/6): capivasertib + fulvestrant vs placebo + fulvestrant
PFS HR 0.60 overall; HR 0.50 in AKT-pathway-altered.
Progression-free survival (overall) (months): Capivasertib + fulvestrant 7.2 (n=355) vs Placebo + fulvestrant 3.6 (n=353) · HR 0.6 · source - Tests AlpelisibHR+/HER2- advanced breast cancer after aromatase inhibitor: alpelisib + fulvestrant vs placebo + fulvestrant, by PIK3CA status
PFS 11.0 vs 5.7 months, HR 0.65 (PIK3CA-mutant).
Progression-free survival (PIK3CA-mutant) (months): Alpelisib + fulvestrant 11 (n=169) vs Placebo + fulvestrant 5.7 (n=172) · HR 0.65 · source - Tests InavolisibFirst-line PIK3CA-mutant HR+/HER2- advanced breast cancer relapsing on/after adjuvant endocrine therapy: inavolisib + palbociclib + fulvestrant vs placebo + palbociclib + fulvestrant
PFS 15.0 vs 7.3 months, HR 0.43; OS 34.0 vs 27.0 months, HR 0.67.
Progression-free survival (months): Inavolisib + palbociclib + fulvestrant 15 (n=161) vs Placebo + palbociclib + fulvestrant 7.3 (n=164) · HR 0.43 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cutaneous adverse reactions · CAPItello-291 | 56% | 15% |
| Diarrhoea · CAPItello-291 | 77% | 12% |
| Fatigue · CAPItello-291 | 38% | 1.9% |
| Stomatitis · CAPItello-291 | 25% | 1.9% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Take with food.
- Between Capivasertib, Alpelisib, Inavolisib and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in CAPItello-291 and SOLAR-1, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Capivasertib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (pik3ca, akt1 or pten alteration), which of the standard options do you recommend and why?Why: Guideline options include: Capivasertib with fulvestrant (CAPItello-291); alpelisib with fulvestrant for PIK3CA (SOLAR-1); inavolisib with palbociclib and fulvestrant for PIK3CA-mutant disease relapsing during or soon after adjuvant endocrine therapy (INAVO120).
- Am I a candidate for Capivasertib, Alpelisib, Inavolisib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CAPItello-291 and SOLAR-1 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
No targetable alteration
Fulvestrant with abemaciclib (postMONARCH), everolimus with exemestane, or another endocrine agent; giredestrant with everolimus is emerging (evERA).
Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer.
An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant.
Exemestane is a steroidal aromatase inhibitor, the partner of everolimus and the agent tested with ovarian suppression in young women.
- Tests AbemaciclibHR+/HER2- advanced breast cancer after progression on CDK4/6 + endocrine therapy: abemaciclib + fulvestrant vs placebo + fulvestrant
PFS 6.0 vs 5.3 months, HR 0.73.
Progression-free survival (months): Abemaciclib + fulvestrant 6 (n=182) vs Placebo + fulvestrant 5.3 (n=186) · HR 0.73 · source - Tests EverolimusER+/HER2- advanced breast cancer after CDK4/6 inhibitor: giredestrant + everolimus vs standard endocrine therapy + everolimus
PFS HR 0.56 (ITT); HR 0.38 (ESR1-mutant).
Progression-free survival (ITT) (months): Giredestrant + everolimus 8.77 vs Standard ET + everolimus 5.49 · HR 0.56 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · 37-46% any grade; 19-32% grade 3-4 | 42% | 19% |
| Diarrhoea · 81-90% any grade; 8-20% grade 3 across trials | 85% | 8% |
| Infections · monarchE / MONARCH 2 | - | 3% |
| Venous thromboembolism · 2-5% across trials | - | 2% |
- Avoid grapefruit. Diarrhoea: start loperamide at the first loose stool.
- Reduce to once daily in severe impairment.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Avoid grapefruit. Live vaccines are contraindicated.
- 7.5 mg (mild), 5 mg (moderate), 2.5 mg (severe).
- Take after a meal.
- Between Abemaciclib, Everolimus and Exemestane, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in postMONARCH and evERA, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Abemaciclib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (no targetable alteration), which of the standard options do you recommend and why?Why: Guideline options include: Fulvestrant with abemaciclib (postMONARCH), everolimus with exemestane, or another endocrine agent; giredestrant with everolimus is emerging (evERA).
- Am I a candidate for Abemaciclib, Everolimus, Exemestane, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of postMONARCH and evERA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Endocrine-refractory, HER2-low or ultralow
Trastuzumab deruxtecan before chemotherapy (DESTINY-Breast06), then sacituzumab govitecan (TROPiCS-02) or datopotamab deruxtecan (TROPION-Breast01) after chemotherapy.
Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.
The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer.
Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy.
- Tests Trastuzumab deruxtecanHR+ HER2-low/ultralow breast cancer after endocrine therapy, chemotherapy-naive: T-DXd vs chemotherapy
PFS HR 0.62.
Progression-free survival, HER2-low (BICR) (months): Trastuzumab deruxtecan 13.2 (n=359) vs Chemotherapy (TPC) 8.1 (n=354) · HR 0.62 · source - Tests Sacituzumab govitecanHR+/HER2- metastatic breast cancer after endocrine therapy, CDK4/6, and 2-4 chemotherapies: sacituzumab govitecan vs chemotherapy
OS 14.4 vs 11.2 months, HR 0.79.
Progression-free survival (months): Sacituzumab govitecan 5.5 (n=272) vs Chemotherapy 4 (n=271) · HR 0.66 · source - Tests Datopotamab deruxtecanHR+/HER2- metastatic breast cancer after endocrine and 1-2 chemotherapies: Dato-DXd vs chemotherapy
PFS HR 0.63; OS HR 1.01.
Progression-free survival (BICR) (months): Datopotamab deruxtecan 6.9 (n=365) vs Chemotherapy (ICC) 4.9 (n=367) · HR 0.63 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 18% |
| Nausea · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Anaemia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Fatigue · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 6% |
- Interstitial lung disease in 10-15%: hold for any respiratory symptom and image; permanently discontinue for grade 2 or above. Moderately emetogenic: three-drug prophylaxis.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · ASCENT, Trodelvy arm, n=258 | 78% | 49% |
| Diarrhoea · ASCENT, Trodelvy arm, n=258 | 59% | 11% |
| Anaemia · ASCENT, Trodelvy arm, n=258 | 94% | 9% |
| Fatigue · ASCENT, Trodelvy arm, n=258 | 65% | 6% |
- UGT1A1*28 homozygotes: higher neutropenia risk; G-CSF prophylaxis is often used.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Stomatitis · TROPION-Breast01, n=360 | 59% | 7% |
| Fatigue · TROPION-Breast01, n=360 | 44% | 4.2% |
| Nausea · TROPION-Breast01, n=360 | 56% | 1.4% |
| Keratitis · TROPION-Breast01, n=360 | 24% | 1.1% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Between Trastuzumab deruxtecan, Sacituzumab govitecan and Datopotamab deruxtecan, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in DESTINY-Breast06 and TROPiCS-02, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Trastuzumab deruxtecan or Sacituzumab govitecan are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (endocrine-refractory, her2-low or ultralow), which of the standard options do you recommend and why?Why: Guideline options include: Trastuzumab deruxtecan before chemotherapy (DESTINY-Breast06), then sacituzumab govitecan (TROPiCS-02) or datopotamab deruxtecan (TROPION-Breast01) after chemotherapy.
- Am I a candidate for Trastuzumab deruxtecan, Sacituzumab govitecan, Datopotamab deruxtecan, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DESTINY-Breast06 and TROPiCS-02 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Germline BRCA carriers
Olaparib (OlympiAD) or talazoparib (EMBRACA) in place of chemotherapy.
Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.
Talazoparib is a PARP inhibitor that traps PARP on DNA about 100 times more strongly than olaparib, which is why it works at a 1 mg daily dose. It is approved for germline BRCA-mutant HER2-negative breast cancer and, with enzalutamide, for HRR-mutant castration-resistant prostate cancer; anaemia is its dominant side effect.
- Tests OlaparibGermline BRCA-mutated, HER2-negative metastatic breast cancer after up to two chemotherapy lines: olaparib vs physician's choice chemotherapy
PFS 7.0 vs 4.2 months, HR 0.58; OS 19.3 vs 17.1 months, not significant.
Progression-free survival (months): Olaparib 7 (n=205) vs Chemotherapy 4.2 (n=97) · HR 0.58 · source - Tests TalazoparibGermline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer: talazoparib vs physician's choice chemotherapy
PFS 8.6 vs 5.6 months, HR 0.54; OS HR 0.85, not significant.
Progression-free survival (months): Talazoparib 8.6 (n=287) vs Chemotherapy 5.6 (n=144) · HR 0.54 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Anaemia · OlympiA adjuvant, n=911 | 24% | 9% |
| Neutropenia · OlympiA adjuvant, n=911 | 16% | 5% |
| Leukopenia · OlympiA adjuvant, n=911 | 17% | 3% |
| Fatigue · OlympiA adjuvant, n=911 | 42% | 1.8% |
- Avoid grapefruit and Seville oranges.
- 200 mg twice daily for CrCl 31-50.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- 0.75 mg daily for CrCl 30-59; 0.5 mg for 15-29.
- Between Olaparib and Talazoparib, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in OlympiAD and EMBRACA, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Olaparib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (germline brca carriers), which of the standard options do you recommend and why?Why: Guideline options include: Olaparib (OlympiAD) or talazoparib (EMBRACA) in place of chemotherapy.
- Am I a candidate for Olaparib, Talazoparib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of OlympiAD and EMBRACA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.